[Skip to content]

Mid Cheshire Hospitals - NHS Foundation Trust
Departments and services How To Find Us
Search our Site

Cancer - Trials in follow-up



This trial is to help decide whether radiotherapy is necessary for women with a particular type of breast cancer. There is some evidence that, in older women, radiotherapy may not always be needed and, like many treatments, it has both short and long term side effects. Apart from the existing evidence that radiotherapy may not be needed in older women, it may not be required in women who are at low risk of the cancer returning. 


The SUPREMO breast cancer trial (Selective Use of Postoperative Radiotherapy aftEr MastectOmy) aims to establish the benefits of postoperative radiotherapy to the chest wall in patients who are at intermediate risk of recurrence.



This trial wants to see if a four-week course of hormone-blocking drugs called aromatase inhibitors, started two weeks before breast cancer surgery, can improve the long term outlook for patients with breast cancer. It also wants to see if changes to cancer cells caused by these drugs allow us to predict which patients respond best to hormone-blocking drugs. Finding tests that show who responds best to these drugs will allow cancer treatment to be tailored more accurately for future patients.


This study is for patients who have had surgery to remove early (primary) breast cancer. The patient may also have received chemotherapy (treatment with drugs) and/or radiotherapy around the time of their surgery. Both these treatments reduce the risk of their cancer returning but they cannot reduce the risk completely. Patients are being asked if they would like to take part in this study, which will look at the experimental use of a drug called celecoxib to further reduce the risk of their cancer returning.


This study is for patients who do not want to take part in the Mammo-50 Main study. However, they gave their permission for their progress to be monitored while they had any future mammograms and breast cancer follow-up.


Persephone is a trial which aims to establish what is the best length of trastuzumab treatment for patients with Her2+ breast cancer. The optimum trastuzumab duration has not yet been determined as when the drug was first manufactured there was no obvious scientific argument for administering it for 12 months. The purpose of the Persephone trial is to confirm whether shorter treatment with trastuzumab for 6 months is as clinically effective and better tolerated than 12 months.  


The purpose of this study is to create a registry (set of information) of men with male breast cancer (male BC), collecting information over a period of 30 months. To be able to better understand and treat male BC, the trial would like to collect information and biological material from men with this disease to learn more about it, and with the long term aim of running research studies to test new treatments.



The study aims to find out when radiotherapy should be used after surgery for prostate cancer.  Radiotherapy may be used after surgery for prostate cancer at one of two different times: it may either be used within a few months after surgery to reduce the risk of cancer recurrence in the future or, alternatively, it may be used later to treat recurrent disease if it occurs. Radicals will compare these two approaches.  Radiotherapy is often used in combination with surgery in other types of cancer. This is because it is often better for patients than using surgery alone. In prostate cancer, surgery alone is a standard approach, and the trial wants to know if adding radiotherapy would be better.


The study will answer important questions for men who have had surgery for prostate cancer, and are now due to have radiotherapy. The trial would like patients to help find out which is the best way to use hormone treatment in men having radiotherapy after surgery for prostate cancer.


The purpose of this study is to document how patients are treated across different hospitals (both in UK and other countries), how the treatments control the disease, the tolerance of the treatments and patient quality of life. Analysis of the collected data may help doctors have a better understanding of how best to treat their patients with prostate cancer in the future.


This Trial is a randomised-controlled trial comparing transcutaneous oestrogen patches (hormone patches) versus LHRH analogues (hormone injections) in men with prostate cancer who are on long term hormone treatment .



Rectal cancer treatment has improved greatly over recent years. However, it is important to learn as much about the tumours as possible in order to develop newer therapies. Current treatments may benefit from new genetic information relating to the cancer. The trial hopes to identify genetic differences in certain types of rectal cancer which will allow future treatments. 


Chemotherapy for bowel cancer is usually given after surgery but studies in other types of cancer have found that giving it before surgery is better than after surgery. The aim of the FOxTROT study is to find out whether giving some of the chemotherapy before surgery reduces the risk of bowel cancer coming back.


Routinely, patients with bowel cancer have received 24 weeks of chemotherapy treatment after surgery. This study is trying to find out if 12 weeks of chemotherapy is just as effective as 24 weeks, with fewer side effects. 



The main goal of this clinical trial is to find out if a drug called Celecoxib makes the standard treatments for bladder cancer work better and also to see how patients tolerate this drug.

Barretts Oesophagus


This study is looking at the best way of managing patients with Barrett’s Oesophagus by making comparisons in care options. Patients are randomly allocated to one of two groups. 1) A planned endoscopy every two years or in between times if the patient needs one. 2) Only being offered an endoscopy if the patient needs one.

Follicular Lymphoma


The aim of the PACIFICO trial is to compare a drug combination known as “R-FC lite” to the drug combination currently regarded as the standard of care (“R-CVP”) to see which is better.

Head & Neck 5000 Head and Neck 5000

The aim of the research is to look at care for people with head and neck cancer. This will be the largest study to examine the factors that affect outcome for people with head and neck cancer. This study will help to understand more about head and neck cancer and how care for people diagnosed with one of these cancers can be improved.

Latest news